Exploring the potential mechanism of artemisinin against gastric cancer based on network pharmacology, machine learning and experimental validation

Background Artemisinin, a natural active component extracted from Artemisia annua , exhibits potential anti-gastric cancer activity; however, its specific targets and molecular mechanisms remain unclear. Methods Network pharmacology was used to predict the potential targets of artemisinin. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed to identify gastric cancer-related genes. Candidate targets of artemisinin against gastric cancer were obtained by intersecting the above datasets. Three machine learning algorithms, namely random forest, LASSO regression, and SVM-RFE, were further employed to screen hub targets, followed by molecular docking to evaluate the binding affinity between artemisinin and the hub targets. Finally, anti-gastric cancer effects and mechanisms were validated by in vitro experiments (CCK-8, EdU, colony formation, Transwell and Western blot). Results A total of 27 candidate targets of artemisinin against gastric cancer were identified. Cross-screening by the three machine learning algorithms ultimately identified TOP2A , CCNB2 , and CCNA2 as hub targets. Molecular docking revealed low binding energies (all below −5.0 kcal/mol) between artemisinin and these three targets, suggesting potential binding affinity. In vitro experiments demonstrated that artemisinin significantly downregulated the mRNA expression levels of the three targets and suppressed the proliferation, migration, and invasion of gastric cancer cells. Mechanistic investigation showed that artemisinin treatment decreased p-ERK levels, and the anti-gastric cancer effects of artemisinin were partially reversed by the ERK pathway activator C16-PAF. Conclusions In vitro , artemisinin suppresses ERK/MAPK pathway activation and reduces the mRNA expression of cell cycle-related TOP2A , CCNB2 and CCNA2 , leading to inhibited proliferation, migration and invasion of gastric cancer cells.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-10-27
DOI
https://doi.org/10.3389/fonc.2026.1931227
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the potential mechanism of artemisinin against gastric cancer based on network pharmacology, machine learning and experimental validation

Chenchen Hu, Jiageng He, Bowen Hou, Changhui Deng et al.
4 links
Frontiers in Oncology
Computational Drug Discovery Methods
article

Exploring the potential mechanism of artemisinin against gastric cancer based on network pharmacology, machine learning and experimental validation

Chenchen Hu, Jiageng He, Bowen Hou, Changhui Deng, Yong Li, Minghui Yun, Yu Shen, Bin Liu, Yu Zhao, Weimin Lian
article en

Abstract

Background Artemisinin, a natural active component extracted from Artemisia annua , exhibits potential anti-gastric cancer activity; however, its specific targets and molecular mechanisms remain unclear. Methods Network pharmacology was used to predict the potential targets of artemisinin. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed to identify gastric cancer-related genes. Candidate targets of artemisinin against gastric cancer were obtained by intersecting the above datasets. Three machine learning algorithms, namely random forest, LASSO regression, and SVM-RFE, were further employed to screen hub targets, followed by molecular docking to evaluate the binding affinity between artemisinin and the hub targets. Finally, anti-gastric cancer effects and mechanisms were validated by in vitro experiments (CCK-8, EdU, colony formation, Transwell and Western blot). Results A total of 27 candidate targets of artemisinin against gastric cancer were identified. Cross-screening by the three machine learning algorithms ultimately identified TOP2A , CCNB2 , and CCNA2 as hub targets. Molecular docking revealed low binding energies (all below −5.0 kcal/mol) between artemisinin and these three targets, suggesting potential binding affinity. In vitro experiments demonstrated that artemisinin significantly downregulated the mRNA expression levels of the three targets and suppressed the proliferation, migration, and invasion of gastric cancer cells. Mechanistic investigation showed that artemisinin treatment decreased p-ERK levels, and the anti-gastric cancer effects of artemisinin were partially reversed by the ERK pathway activator C16-PAF. Conclusions In vitro , artemisinin suppresses ERK/MAPK pathway activation and reduces the mRNA expression of cell cycle-related TOP2A , CCNB2 and CCNA2 , leading to inhibited proliferation, migration and invasion of gastric cancer cells.

Frontiers in OncologyVol. 16
Shihezi University (CN), First Affiliated Hospital of Shihezi University Medical College (CN)
Good health and well-being
Openalex Percentile: Top 14%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon